Link: Biospace.com.
Cepheid (Nasdaq: CPHD – News), a broad-based molecular diagnostics company, today announced it received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(TM) MRSA test, which runs on the GeneXpert System, for the rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA). Xpert MRSA results, delivered in just over one hour, rapidly identify carriers of the potential pathogen and enable healthcare organizations to implement the proper infection control measures, leading to lower hospital acquired infection rates while improving patient care.
{ 2 comments… read them below or add one }
I would like to know the unit cost for this test and if you need to be a doctor to do it. I run a sports/fireman “cleaning & Sanitizing” business and this could be a new product for me to sell/administer to my clientele.
Charles Pendrak
Clean Gear of Philadelphia, Inc.
610-299-3485
I would like to know the unit cost for this test and if you need to be a doctor to do it. I run a sports/fireman “cleaning & Sanitizing” business and this could be a new product for me to sell/administer to my clientele.
Charles Pendrak
Clean Gear of Philadelphia, Inc.
610-299-3485